Resistant cases of psoriatic arthritis: How to manage them

Journal of Rheumatology

Volumn 36, Issue SUPPL. 83, 2009, Pages 73-75

  Atzeni, Fabiola ^a   Sarzi Puttini, Piercarlo ^a   Vena, Gino Antonio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Anti tumor necrosis factor agents; Disease modifying antirheumatic drugs; Psoriasis; Psoriatic arthritis

Indexed keywords

ADALIMUMAB; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ARTHRITIS; CAUCASIAN; CHRONIC INFLAMMATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISABILITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ENTHESITIS; HUMAN; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MONARTHRITIS; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; RHEUMATOID ARTHRITIS; TREATMENT INDICATION; ALGORITHM; ARTICLE; DRUG ANTAGONISM; DRUG COMBINATION; DRUG RESISTANCE;

ALGORITHMS; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349904454     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090232     Document Type: Conference Paper

References (23)

1. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat 2006;17:96-107.
2. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 Suppl 2;ii14-7. (Pubitemid 40288513)
3. Scarpa R, Cuocolo A, Peluso R, et al. Early psoriatic arthritis: the clinical spectrum. J Rheumatol 2008;35:137-141
4. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm Venereol 2002;82:108-113 (Pubitemid 34596683)
5. Gladman DD, Farewell VT,Wong K, Husted J.Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998;41:1103-1110
6. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat 2008;19:5-21.
7. Winterfield LS, Menter A, Gordon K, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005;64 Suppl 2:ii87-90. (Pubitemid 40288531)
8. Cassano N, Mastrandrea V, Buquicchio R, et al. Efalizumab in moderate-to-severe plaque psoriasis: a retrospective case series analysis from clinical practice. J Biol Regul Homeost Agents 2008;22:185-193
9. Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB. Efalizumab: results of a 3-year continuous dosing study for the long term control of psoriasis. Br J Dermatol 2008;158:1107-1116
10. Tobin AM, Kirby B. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005;19:47-57. (Pubitemid 40432507)
11. Moll JMH, Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973;3:55-78.
12. Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB. Macrophage-derived cytokine and nuclear factor kB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 2000;43:1244-1256 (Pubitemid 30416309)
13. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe resistant psoriatic arthritis. Clin Exp Rheumatol 2000;18:732-734
14. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-390 (Pubitemid 30487495)
15. Atzeni F, Sarzi-Puttini P, DePortu S, Cutolo M, Carrabba M, Straub RH. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. Clin Exp Rheumatol 2008;26:103-108
16. Kamarashev J, Lor P, Forster A, Heinzerling L, Burg G, Nestle FO. Generalised pustular psoriasis induced by cyclosporin withdrawal responding to the tumour necrosis factor alpha inhibitor alpha etanercept. Dermatology 2002;205:213-216
17. Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe agents. pustular psoriasis, von Zumbusch type. Int J Dermatol 2002;41:449-452 (Pubitemid 34905082)
18. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005;52:1227-1236 (Pubitemid 40530131)
19. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: two-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2008 August 6. E-pub ahead of print.
20. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 2007;56:476-488
21. Canete JD, Santiago B, Sanmarti R, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007;66:720-726 (Pubitemid 46846689)
22. Mielke F, Schneider-Obermeyer J, Dörner T. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma. Ann Rheum Dis 2008;67:1056-1057 (Pubitemid 351956683)
23. Cohen JD. Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008;67:1647-1648